Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG
Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG
Abstract BackgroundThe investigation of antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared one new and four widely used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) protein. MethodsSerum samples from a group of apparently non-responders, from an unbiased group of convalescent patients and from a negative control group were sim-ultaneously analyzed by the LIAISON? SARS-CoV-2 S1/S2 IgG test, Euroimmun anti-SARS-CoV-2 S1 IgG ELISA and IDK? anti-SARS-CoV-2 S1 IgG assays. IgG binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the panimmunoglobulin immunoassay Elecsys? Anti-SARS-CoV-2. Additionally, samples were also tested by live virus and pseudovirus neutralization tests. ResultsOverall, about 50% of convalescent patients with undetectable IgG antibodies using the commercial kit by Euroimmun were identified as IgG positive by Immundiagnostik and Roche. While both assays achieved similarly high sensitivities, Immundiagnostik correlated better with serum neutralizing activity than Roche. ConclusionsAlthough the proportion of IgG seropositive individuals appears to be higher using more sensitive immunoassays, the protective ability and the potential to serve as indirect markers of other beneficial immune responses warrants for further research.
Brensing Karl August、Di Cristanziano Veronica、Kleipass Franziska、Augustin Max、Vanshylla Kanika、Wirtz Maike、Dewald Felix、Gieselmann Lutz、Lehmann Clara、Schommers Philipp、Johannis Wibke、Eberhardt Kirsten Alexandra、Klein Florian、M¨1ller Roman-Ulrich、Heger Eva、Gruell Henning、Koch Manuel
Nierenzentrum BonnInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Center for Molecular Medicine Cologne (CMMC), University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of CologneDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Center for Molecular Medicine Cologne (CMMC), University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Center for Molecular Medicine Cologne (CMMC), University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of CologneCenter for Molecular Medicine Cologne (CMMC), University of Cologne||Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne||German Center for Infection Research (DZIF), Partner Site Bonn-CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne||German Center for Infection Research (DZIF), Partner Site Bonn-CologneInstitute for Clinical Chemistry, Faculty of Medicine and University Hospital of Cologne, University of CologneDepartment of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Dep. of Medicine University Medical Center Hamburg-Eppendorf||Institute for Transfusion Medicine, University Medical Center Hamburg-EppendorfInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Center for Molecular Medicine Cologne (CMMC), University of Cologne||German Center for Infection Research (DZIF), Partner Site Bonn-CologneCenter for Molecular Medicine Cologne (CMMC), University of Cologne||Department II of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne||Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, CECAD, University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of CologneInstitute of Virology, Faculty of Medicine and University Hospital of Cologne, University of Cologne||German Center for Infection Research (DZIF), Partner Site Bonn-CologneCenter for Molecular Medicine Cologne (CMMC), University of Cologne||Institute for Experimental Dentistry and Oral Musculoskeletal Biology, and Center for Biochemistry, Faculty of Medicine and University Hospital of Cologne, University of Cologne
医学研究方法基础医学微生物学
pandemichumoral responseneutralizationtiterprotectionnon-respondercoro-navirusantibodyCOVID-19sensitivity
Brensing Karl August,Di Cristanziano Veronica,Kleipass Franziska,Augustin Max,Vanshylla Kanika,Wirtz Maike,Dewald Felix,Gieselmann Lutz,Lehmann Clara,Schommers Philipp,Johannis Wibke,Eberhardt Kirsten Alexandra,Klein Florian,M¨1ller Roman-Ulrich,Heger Eva,Gruell Henning,Koch Manuel.Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG[EB/OL].(2025-03-28)[2025-05-21].https://www.medrxiv.org/content/10.1101/2021.03.10.21253288.点此复制
评论